FDA Cancer Drug Approvals Show Troubling Shift Toward Surrogate Endpoints and Single-Arm Trials Over Two Decades
核心洞察
A new JAMA (搜索) study analyzing 20 years of FDA cancer drug approvals reveals increasing reliance on surrogate endpoints and single-arm trials, including outside the accelerated approval pathway.
Researchers found that many recent regular approvals are based on weak surrogate endpoints rather than using the accelerated approval pathway, which requires confirmatory trials.
The study highlights that premature regular approval removes the safety net of confirmatory trial requirements and the ability to withdraw drugs that fail to demonstrate clinical benefit.
A comprehensive new study published in JAMA (搜索) has examined how the FDA's cancer drug approval landscape has shifted over the past two decades, uncovering concerning trends in the types of evidence used to bring oncology therapies to market.
The research, led by Brian Shkabari of the Sinclair Cancer Research Institute (搜索) alongside colleagues from the BG Lab, reviewed 20 years of FDA approvals for cancer drugs to assess how regulatory standards have evolved over time.
Growing Reliance on Surrogate Endpoints
The study identified an increasing dependence on surrogate endpoints as the basis for cancer drug approvals. While surrogate endpoints can accelerate patient access to promising therapies, their use outside the FDA's accelerated approval pathway raises significant questions about the strength of evidence supporting new cancer medicines.
The findings point to a notable trend: many recent approvals based on surrogate endpoints have been granted as regular approvals rather than through the accelerated approval mechanism. This pattern has drawn sharp criticism from the research team.
Accelerated Approval Pathway Underutilized
Bishal Gyawali, medical oncologist and professor at Queen's University and senior author of the study, highlighted a critical concern regarding the underutilization of the accelerated approval (AA) pathway.
"The AA pathway provides a good balance between speed and evidence," Gyawali stated. "But what we found is that most approvals based on surrogate endpoints in recent years is in fact regular approval rather than AA."
Gyawali warned that granting upfront premature regular approval removes essential safeguards built into the regulatory system. "It removes the safety net of confirmatory trial requirement that verifies clinical benefit. It also removes the safety net of withdrawing drugs that don't benefit patients," he explained. "The AA pathway exists for a reason."
Single-Arm Trial Data Under Scrutiny
The study also documented an increased reliance on single-arm trials as the evidentiary foundation for cancer drug approvals. This trend, combined with the shift away from the accelerated approval pathway, suggests a broader loosening of evidentiary standards that the authors find concerning.
"There is zero logic to providing regular approval instead of AA based on weak surrogate endpoints," Gyawali concluded.
Implications for Clinical Practice
The findings carry significant implications for oncologists and patients, as drugs approved on the basis of surrogate endpoints without confirmatory trial requirements may enter clinical practice with less certainty about their real-world clinical benefit. The study underscores the importance of the accelerated approval pathway's built-in mechanisms for verifying that promising early data translates into meaningful patient outcomes.
Brian Shkabari, reflecting on the publication, described the paper as a career milestone and indicated that more work from the research group is forthcoming.